EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Integration of 24‐h Urine Aldosterone & Tetrahydroaldosterone With Plasma Screening for Primary Aldosteronism: A 7‐Year Study

Jenny Yeuk Ki Cheng, Timothy Hua-Tse Cheng, Edith Wing Kar Chow, Wendy Wan Hang Lau, Kitty Kit Ting Cheung, Clara Wai Shan Lo, Teresa Kam Chi Tsui, Risa Ozaki, Ronald Ching Wan Ma, Chung Shun Ho

The Journal of Clinical Hypertension · 2026-11 · 28 (11)

DOI: 10.1111/jch.70390 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Clinical Hypertension, online erschienen am 20.11.2026. Verfasst von Jenny Yeuk Ki Cheng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, People's Republic of China. Hauptthemen laut MEDLINE: Hyperaldosteronism, Aldosterone, Mass Screening. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plasma‐based screening for primary aldosteronism (PA), namely aldosterone‐to‐renin ratio, plasma aldosterone concentration (PAC), and plasma renin activity (PRA), is influenced by short‐term physiologic variation and medications. Non‐salt‐loaded 24‐h urine collection may complement plasma screening. In this multicenter retrospective observational study (October 2013–September 2020), non‐salt‐loaded 24‐h urinary aldosterone (UALD) and tetrahydroaldosterone (UTHA) were measured by liquid chromatography–tandem mass spectrometry (LC–MS/MS) in patients evaluated for PA. A chronological derivation (2013–2015) and validation (2015–2020) design was used. Optimal cutoffs for UALD, UTHA, and their sum (SUM) were derived using ROC analysis with bootstrapping. In patients with paired urine and plasma measurements, logistic models were developed for a urine panel (UALD, UTHA), a plasma panel (PAC, PRA), and a combined panel. A points‐based Combined Urine–Plasma Score (CUPS) was constructed for clinical implementation. Among 1316 eligible cases, derived cutoffs were UALD >39 nmol/day, UTHA >179 nmol/day, and SUM >190 nmol/day, all with AUCs of 0.84–0.85. In 1076 cases, AUCs were 0.85 for the urine panel, 0.89 for the plasma panel, and 0.93 for the combined panel. The combined panel achieved 89% sensitivity and 84% specificity (positive predictive value 59%, negative predictive value (NPV) 97%), improving sensitivity compared with Endocrine Society rule‐based screening (66%) but with similar specificity (89%). CUPS showed comparable performance (sensitivity 85%, specificity 86%, NPV 96%). Non‐salt‐loaded 24‐h urinary aldosterone biomarkers measured by LC–MS/MS provide robust screening performance and add incremental value to plasma‐based screening. Integrating urine and plasma markers (including CUPS) may improve PA detection in routine practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperaldosteronismAldosteroneMass ScreeningHumansFemaleRetrospective StudiesMiddle AgedReninTandem Mass SpectrometryMaleChromatography, LiquidLiquid Chromatography-Mass SpectrometryROC CurveSensitivity and SpecificityAdult

Stichwörter der Autor:innen

aldosteroneprimary aldosteronismscreeningtetrahydroaldosterone

Substanzen

AldosteroneRenin

Autor:innen und Institutionen

  • Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
  • Department of Chemical Pathology, Prince of Wales Hospital, Hong Kong, People's Republic of China.
  • Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, People's Republic of China.
  • Phase 1 Clinical Trial Center, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
  • Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.
  • Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, People's Republic of China.

Zitieren

APA

Cheng, J. Y. K., Cheng, T. H., Chow, E. W. K., Lau, W. W. H., Cheung, K. K. T., Lo, C. W. S., Tsui, T. K. C., Ozaki, R., Ma, R. C. W., & Ho, C. S. (2026). Integration of 24‐h Urine Aldosterone & Tetrahydroaldosterone With Plasma Screening for Primary Aldosteronism: A 7‐Year Study. The Journal of Clinical Hypertension, 28(11). https://doi.org/10.1111/jch.70390

Vancouver

Cheng JYK, Cheng TH, Chow EWK, Lau WWH, Cheung KKT, Lo CWS, et al. Integration of 24‐h Urine Aldosterone & Tetrahydroaldosterone With Plasma Screening for Primary Aldosteronism: A 7‐Year Study. The Journal of Clinical Hypertension. 2026;28(11). doi:10.1111/jch.70390

BibTeX
@article{Cheng2026,
  author = {Cheng, Jenny Yeuk Ki and Cheng, Timothy Hua-Tse and Chow, Edith Wing Kar and Lau, Wendy Wan Hang and Cheung, Kitty Kit Ting and Lo, Clara Wai Shan and Tsui, Teresa Kam Chi and Ozaki, Risa and Ma, Ronald Ching Wan and Ho, Chung Shun},
  title = {Integration of 24‐h Urine Aldosterone & Tetrahydroaldosterone With Plasma Screening for Primary Aldosteronism: A 7‐Year Study},
  journal = {The Journal of Clinical Hypertension},
  year = {2026},
  volume = {28},
  number = {11},
  doi = {10.1111/jch.70390}
}
Kostenlos starten →